Adagio Medical, Inc.

Special purpose acquisition corporations did not have a very successful run in the last SPAC wave to hit the life science sector, but a new round of the vehicles that provide companies an alternative

Farapulse and Medtronic expect pulsed field ablation (PFA) technology to eventually dominate the US atrial fibrillation ablation catheter market, but the companies are sponsoring very different US

Southern California-based cardiac ablation technology developer Adagio Medical, Inc. closed a $42.5m series E equity financing on 12 November. The new funds will support the ongoing investigational

Biopharma companies closed 70 deals around the four major neurodegenerative diseases – Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Amyotrophic Lateral Sclerosis – in the period Jan